» Articles » PMID: 7885450

Association of Cdk-activating Kinase Subunits with Transcription Factor TFIIH

Overview
Journal Nature
Specialty Science
Date 1995 Mar 16
PMID 7885450
Citations 141
Authors
Affiliations
Soon will be listed here.
Abstract

The RNA polymerase II large subunit contains an essential carboxy-terminal domain (CTD) believed to be involved in the response to regulators during transcription initiation. The CTD is phosphorylated on a portion of RNA polymerase II molecules in vivo and it can be phosphorylated by the general transcription factor TFIIH in vitro. A highly purified TFIIH from rat liver has been described; this, like human and yeast TFIIH, contains associated CTD kinase and helicase activities. We report here that two polypeptides of the purified mammalian TFIIH are the MO15/Cdk7 kinase and cyclin H subunits of the Cdk-activating kinase Cak, previously identified as a positive regulator of Cdc2 and Cdk2. TFIIH and Cak preparations are each capable of phosphorylating recombinant CTD and recombinant Cdk2 proteins. The presence of Cak in TFIIH indicates that Cak may have roles in transcriptional regulation and in cell-cycle control.

Citing Articles

CTDP1 and RPB7 stabilize Pol II and permit reinitiation.

Zheng H, Xu Q, Ji D, Yang B, Ji X Nat Commun. 2025; 16(1):2161.

PMID: 40038320 PMC: 11880454. DOI: 10.1038/s41467-025-57513-2.


Structural basis of Cdk7 activation by dual T-loop phosphorylation.

Duster R, Anand K, Binder S, Schmitz M, Gatterdam K, Fisher R Nat Commun. 2024; 15(1):6597.

PMID: 39097586 PMC: 11297931. DOI: 10.1038/s41467-024-50891-z.


CDK7 in breast cancer: mechanisms of action and therapeutic potential.

Gong Y, Li H Cell Commun Signal. 2024; 22(1):226.

PMID: 38605321 PMC: 11010440. DOI: 10.1186/s12964-024-01577-y.


Structural basis of Cdk7 activation by dual T-loop phosphorylation.

Duster R, Anand K, Binder S, Schmitz M, Gatterdam K, Fisher R bioRxiv. 2024; .

PMID: 38405971 PMC: 10888979. DOI: 10.1101/2024.02.14.580246.


Cyclin-dependent kinase 7 (CDK7) inhibitors as a novel therapeutic strategy for different molecular types of breast cancer.

Song X, Fang C, Dai Y, Sun Y, Qiu C, Lin X Br J Cancer. 2024; 130(8):1239-1248.

PMID: 38355840 PMC: 11014910. DOI: 10.1038/s41416-024-02589-8.